Related Experiment Videos
Treatment of hepatitis C
1Department of Medicine, West Los Angeles VA Medical Center, Los Angeles, California, USA.
The American Journal of Medicine
|August 9, 2005
Summary
Hepatitis C virus (HCV) infection causes chronic liver disease and is a leading cause for liver transplants. Current standard therapy, peginterferon and ribavirin, has significant side effects, prompting research into new strategies.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) is a major global health concern, causing chronic liver disease in over 170 million people.
- HCV infection is the primary indication for liver transplantation and can lead to severe complications like cirrhosis, hepatic decompensation, and hepatocellular carcinoma.
- Despite extensive research, optimal treatment strategies for chronic HCV infection remain an area of active investigation.
Purpose of the Study:
- To review current treatment strategies for chronic hepatitis C infection.
- To discuss considerations for special patient populations including acute infection, HCV/HIV coinfection, and those with prior treatment failure.
- To highlight the goal of sustained virologic response and the challenges posed by treatment-related adverse effects.
Main Methods:
- Review of existing literature on Hepatitis C virus treatment.
- Analysis of standard therapy regimens and their efficacy.
- Discussion of treatment modifications for specific patient groups.
Main Results:
- The current standard therapy for chronic hepatitis C is peginterferon and ribavirin.
- Treatment approaches vary based on genotype, liver biopsy results, and patient history.
- Adverse effects of interferon alfa and ribavirin can impede treatment adherence.
Conclusions:
- Achieving a sustained virologic response is the primary goal of HCV therapy.
- Managing adverse effects and tailoring treatment for diverse patient groups are critical.
- Further research is needed to optimize HCV treatment and minimize complications.